COMP <GO>
AMRX vs KNSA // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Amneal Pharmaceuticals Inc. (NASDAQ) VS. Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ) • 15-METRIC TALLY: AMRX 5
— KNSA 7
■ METRIC PARITY
LAST: $20.44 (-4.97%) • MKT CAP: $7.12B
options-implied-move
—
LAST: $90.80 (-1.56%) • MKT CAP: $7.13B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. KNSA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | KNSA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 88.50% | -51.60 | KNSA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 9.90% | +4.20 | AMRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.4x | 95.0x | -73.60 | AMRX | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | 1.78% | +1.85 | AMRX | /fcf-yield <GO> |
| Operating Margin | 13.10% | 11.40% | +1.70 | AMRX | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 8.70% | -6.30 | KNSA | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 60.10% | -52.10 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 24.45 | -20.62 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 57.2 | -6.10 | KNSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.11 | -0.03 | KNSA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 96.0x | 109.1x | -13.10 | AMRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.12B | $7.13B | -$15.1M | KNSA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | KNSA REV | AMRX GROSS % | KNSA GROSS % | AMRX FCF | KNSA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | $677.6M | 36.9% | 88.5% | $269.9M | $136.4M |
| FY 2024 | $2.79B | $423.2M | 36.5% | 85.6% | $243.2M | $25.4M |
| FY 2023 | $2.39B | $270.3M | — | — | $237.9M | $1.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
KNSA // BETA 1.11